Amir Nashat

Amir Nashat serves as an Executive Partner at Polaris Partners. In his role at Polaris, Amir creates and invests in new companies, primarily in biotechnology.

Over his career, Amir has helped launch numerous companies, including Dewpoint Therapeutics, the leading biotechnology company focused on biomolecular condensates; Fate Therapeutics (NASDAQ: FATE); Kojin Therapeutics, the leading company focused on ferroptosis biology; Jnana Therapeutics, a leading chemoproteomics company focused on difficult-to-drug targets in disease; Living Proof, a science-based beauty company acquired by Unilever; Morphic Therapeutic (NASDAQ: MORF); Promedior Pharmaceuticals, a biotechnology company with a novel approach to treat fibrosis acquired by Roche; Scholar Rock (NASDAQ: SRRK); and Sun Catalytix, a renewable energy storage company acquired by Lockheed Martin. 

Amir also serves on the Partners Innovation Fund at Partners/MGH, the Investment Advisory Committee for The Engine at MIT, and helped launch the MIT Sandbox Innovation Fund. He has been named to the Forbes Midas List of “Top 100 Venture Capitalists.” Prior to joining Polaris, Amir completed his ScD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Amir also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley.